Journal
NEURODEGENERATIVE DISEASES
Volume 18, Issue 5-6, Pages 233-238Publisher
KARGER
DOI: 10.1159/000493103
Keywords
Parkinson's disease; Cerebrospinal fluid biomarkers; Cognitive decline; Cortical atrophy; SNCA polymorphism
Categories
Funding
- CERCA
- CIBERNED
- la Marato de TV3 [2014/U/477, 20142910]
- Fondo de Investigaciones Sanitarias del Ministerio de Sanidad y Consumo [PI15/00962, PI14/02058]
Ask authors/readers for more resources
The role of cerebrospinal fluid (CSF) biomarkers such as CSF a-synuclein and CSF tau in predicting cognitive decline in Parkinson's disease (PD) continues to be inconsistent. Here, using a cohort of de novo PD patients with preserved cognition from the Parkinson's Progression Markers Initiative (PPMI), we show that the SNCA rs356181 single nucleotide polymorphism (SNP) modulates the effect of these CSF biomarkers on cortical thinning. Depending on this SNP's genotype, cortical atrophy was associated with either higher or lower CSF biomarker levels. Additionally, this SNP modified age-related atrophy. Importantly, the integrity of the brain regions where this phenomenon was observed correlated with cognitive measures. These results suggest that this genetic variation of the gene encoding the a-synuclein protein, known to be involved in the development of PD, also interferes in its subsequent neurodegeneration. Overall, our findings could shed light on the so far incongruent association of common CSF biomarkers with cognitive decline in PD. (C) 2018 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available